Joseph G. Pressey · Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group
Follow
Article1 min read·Published May 2011Older

Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · May 2011 · 1 min read

In brief

In brief

This Children's Oncology Group study investigated hedgehog pathway activation in pediatric rhabdomyosarcoma and undifferentiated sarcomas by measuring GLI1 and PTCH expression in archived tumor specimens. Results showed significant pathway activity in embryonal RMS and undifferentiated sarcomas but rarely in alveolar RMS, without correlation to specific clinical phenotypes.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Background: Aberrant activation of the hedgehog (Hh) signaling pathway is implicated widely in both pediatric and adult malignancies. Inactivation of the Hh regulator PTCH is responsible for the Gorlin cancer predisposition syndrome. The spectrum of tumors found in Gorlin Syndrome includes basal cell carcinoma, medulloblastoma, and rarely, rhabdomyosarcoma (RMS). A previous report utilizing in situ hybridization has provided initial evidence for the expression of Hh targets GLI1 and PTCH in RMS tumors. Procedure: To investigate the role of Hh pathway signaling in pediatric RMS and undifferentiated sarcoma (US) tumors, the expression of Hh pathway targets GLI1 and PTCH was measured. RNA was extracted from archival human tumor specimens collected from pediatric patients enrolled on Intergroup Rhabdomyosarcoma Study III and IV, and subjected to quantitative reverse transcriptase-polymerase chain reaction. Results: Expression of GLI1 with or without PTCH was detected in substantial subsets of embryonal RMS (ERMS) and US tumors but only rarely in alveolar RMS tumors. Neither PTCH mutations nor activating SMO mutations were detected in ERMS tumors with high GLI1 expression. Microarray analysis demonstrated relative overexpression of downstream Hh targets in ERMS tumors with high or intermediate GLI1 expression. Unlike a recent report, Hh pathway activity in ERMS tumors did not correlate with a unique clinical phenotype. Conclusions: Our findings support a role for Hh pathway activa

Statements in this article

  1. Aberrant activation of the hedgehog signaling pathway is implicated widely in both pediatric and adult malignancies.

    EstablishedBackground
  2. Inactivation of the hedgehog regulator PTCH is responsible for the Gorlin cancer predisposition syndrome.

    EstablishedBackground
  3. The spectrum of tumors found in Gorlin Syndrome includes basal cell carcinoma, medulloblastoma, and rarely, rhabdomyosarcoma.

    EstablishedBackground
  4. Expression of GLI1 with or without PTCH was detected in substantial subsets of embryonal rhabdomyosarcoma and undifferentiated sarcoma tumors but only rarely in alveolar rhabdomyosarcoma tumors.

    ResearchResults
  5. Neither PTCH mutations nor activating SMO mutations were detected in embryonal rhabdomyosarcoma tumors with high GLI1 expression.

    ResearchResults
  6. Microarray analysis demonstrated relative overexpression of downstream hedgehog targets in embryonal rhabdomyosarcoma tumors with high or intermediate GLI1 expression.

    ResearchResults
  7. Hedgehog pathway activity in embryonal rhabdomyosarcoma tumors did not correlate with a unique clinical phenotype.

    ResearchResults

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.